SAP and MolecularHealth, a leader in clinico-molecular informatics have come together to provide cancer patients personalized treatment choices based on the analysis of terabytes of information in real-time.
Oncologist have a challenge of selecting from a host of approved drugs and clinical trials poses, with SAP HANA the Oncologist can bring a dramatic acceleration to their decision-making process. The MolecularHealth offering, supported by the platform, is planned to be capable of translating genomic sequences of both tumor and normal cells — more than 3 billion data points — into potential treatment strategies. Physicians are planned to be able to select a treatment strategy for each patient from hundreds of approved drugs and clinical trials — a process that today involves significant time and complexity. Genomic sequencing data amounts to approximately 2 terabytes of information per patient. Printed on paper, this amount of data would fill a medium-sized elementary school library.
The solution is planned to be deployable in the cloud, on premise or in a hybrid model, as well as to be made available via mobile devices.
“With our market-leading innovations and our investments in research and healthcare IT solutions, we have the ability to support the fight against cancer together with MolecularHealth,” said Jim Hagemann Snabe, co-CEO, SAP AG. “We partner and drive co-innovation with companies that are dedicated to making a difference. Our investment in technologies and platforms such as SAP HANA, cloud and enterprise mobility enables us and our partners to deliver on our vision and commitment to make the world run better and to improve people’s lives.”
SAP HANA is also helping Mitsui Knowledge Industry (MKI) in Japan to shortened genome analysis time from several days to minutes. There goal is to deliver cancer treatments to patients the same day.
More information is available in the press release.